Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? | SpringerLink
Novo Nordisk's PIONEER Trial Will Establish A New Frontier In Oral Anti-Diabetics (NYSE:NVO) | Seeking Alpha
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI | NEJM
![Design of the PIONEER AF-PCI trial [42]. a Creatinine clearance 30-49... | Download Scientific Diagram](https://www.researchgate.net/publication/332352082/figure/fig2/AS:746553086058496@1555003534230/Design-of-the-PIONEER-AF-PCI-trial-42-a-Creatinine-clearance-30-49-mL-min-10-mg-od-b.png "Design of the PIONEER AF-PCI trial [42]. a Creatinine clearance 30-49... | Download Scientific Diagram")
Design of the PIONEER AF-PCI trial [42]. a Creatinine clearance 30-49... | Download Scientific Diagram
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial - Bain - 2019 - Diabetes, Obesity and Metabolism - Wiley Online Library
Overview of the PIONEER Clinical Trial Program for Oral Semaglutide
Novo Nordisk's PIONEER Trial Will Establish A New Frontier In Oral Anti-Diabetics (NYSE:NVO) | Seeking Alpha
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology
Cardiovascular Outcomes Trial (CVOT) | RYBELSUS® (semaglutide) tablets
Xarelto® (rivaroxaban) – PIONEER
Initiation of Angiotensin-Neprilysin Inhibition after Acute Decompensated Heart Failure: Results of the Open-Label Extension of the PIONEER-HF Trial | tctmd.com
Clinical Research Trials | West Palm Beach | Type 2 Diabetes
The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status - tctmd.com
Transition study and Pioneer HF study
PIONEER AF-PCI Trial: Inclusion and Main Exclusion Criteria and Study... | Download Scientific Diagram
PIONEER-HF (TIMI 62) – TIMI STUDY GROUP
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial - ScienceDirect
PIONEER-HF
31508-6.fp.png "EFFECT OF SACUBITRIL/VALSARTAN INITIATION ON 30-DAY READMISSIONS AFTER A HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE: A SECONDARY ANALYSIS OF THE PIONEER-HF TRIAL | Journal of the American College of Cardiology")
EFFECT OF SACUBITRIL/VALSARTAN INITIATION ON 30-DAY READMISSIONS AFTER A HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE: A SECONDARY ANALYSIS OF THE PIONEER-HF TRIAL | Journal of the American College of Cardiology
PIONEER AF-PCI Trial: Inclusion and Main Exclusion Criteria and Study... | Download Scientific Diagram
PIONEER AF-PCI Trial: Inclusion and Main Exclusion Criteria and Study Design | Radcliffe Cardiology
